Percutaneous Radiofrequency Ablation for hepatocellular Carcinoma: Clinical Outcome and safety in Elderly Patients

Authors

  • Hiroki Nishikawa Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
  • Yukio Osaki Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
  • Eriko Iguchi Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
  • Haruhiko Takeda Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
  • Yoshiaki Ohara Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
  • Azusa Sakamoto Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
  • Keiichi Hatamaru Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
  • Shinichiro Henmi Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
  • Sumio Saito Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
  • Akihiro Nasu Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
  • Ryuichi Kita Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
  • Toru Kimura Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan

Keywords:

Hepatocellular carcinoma, radiofrequency ablation, elderly patients, clinical outcome, safety

Abstract

Background & Aims. We aimed to compare clinical outcomes and safety of radiofrequency ablation (RFA) in single hepatocellular carcinoma (HCC) patients aged >75 years (elderly group) versus patients aged <75 years (control group).

Patients and methods.There were 130 patients in the elderly group and 238 in the control group. Clinical outcomes including overall survival (OS), recurrence free survival (RFS) and local tumor progression (LTP), and safety were analysed for these two groups after initial RFA.

Results. The mean (± standard deviation [SD]) tumor diameter in the elderly and the control groups was 2.13 ± 0.86 cm and 1.92 ± 0.63 cm, respectively; the mean (± SD) observation period was 2.5 ± 1.8 years and 3.2 ± 2.0 years, respectively. The 1 and 3 year OS rates were 90.0 and 64.1%, respectively, in the elderly group and 97.6 and 83.7%, respectively, in the control group (P=0.001); the corresponding RFS rates were 66.9 and 21.3%, respectively, in the elderly group and 80.5 and 40.0%, respectively, in the control group (P=0.001). The 1 and 3 year LTP rates were 15.0 and 43.0%, respectively, in the elderly group and 8.3 and 26.3%, respectively, in the control group (P=0.002). In terms of duration of hospitalization (P=0.807) and serious adverse events related RFA (P=0.670), there was no significant difference between these two groups.

Conclusion. The clinical outcomes in the elderly group were poorer than those in the control group, although RFA in the elderly patients was a safe procedure.

Downloads

Published

2012-12-01

How to Cite

1.
Nishikawa H, Osaki Y, Iguchi E, Takeda H, Ohara Y, Sakamoto A, Hatamaru K, Henmi S, Saito S, Nasu A, Kita R, Kimura T. Percutaneous Radiofrequency Ablation for hepatocellular Carcinoma: Clinical Outcome and safety in Elderly Patients. JGLD [Internet]. 2012 Dec. 1 [cited 2026 Jul. 15];21(4):397-405. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/2012.4.13

Issue

Vol. 21 No. 4: December 2012

Section

Original Article